Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Chimeric Therapeutics Ltd. ( (AU:CHM) ).
Chimeric Therapeutics announced that its novel CAR-T cell therapy, CHM 1107, has been granted Orphan Drug Designation by the FDA for the treatment of gastric cancer. This designation provides the company with incentives such as tax credits and potential market exclusivity, enhancing its position in the cell therapy industry and addressing significant unmet medical needs in gastric cancer treatment.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics, an Australian leader in cell therapy, is focused on developing innovative cancer treatments. The company specializes in both autologous CAR T cell therapies and allogeneic NK cell therapies, with a diversified portfolio targeting various oncology areas through multiple clinical programs.
Technical Sentiment Signal: Sell
Current Market Cap: A$10.93M
Find detailed analytics on CHM stock on TipRanks’ Stock Analysis page.